Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The current toolbox for APOBEC drug discovery.

Trends in pharmacological sciences - 1 May 2022

Grillo Michael J, Jones Katherine F M, Carpenter Michael A, Harris Reuben S, Harki Daniel A

Abstract excerpt

Mutational processes driving genome evolution and heterogeneity contribute to immune evasion and therapy resistance in viral infections and cancer. APOBEC3 (A3) enzymes promote such mutations by catalyzing the deamination of cytosines to uracils in single-stranded DNA. Chemical inhibition of A3 enzymes may yield an antimutation therapeutic strategy to improve the durability of current drug therapies that are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytidine Deaminase
Share to Drug Discovery
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 35272863
DOI: 10.1016/j.tips.2022.02.007
PMCID: PMC9018551

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The current toolbox for APOBEC drug discovery.PMID 35272863Read ↗

Small‐Molecule APOBEC3G DNA Cytosine Deaminase Inhibitors Based on a 4‐Amino‐1,2,4‐triazole‐3‐thiol ScaffoldSemantic proximity Read ↗

Structure-Guided Design of a Potent and Specific Inhibitor against the Genomic Mutator APOBEC3ASemantic proximity Read ↗

APOBEC3 family proteins as drivers of virus evolutionSemantic proximity Read ↗

Active site plasticity and possible modes of chemical inhibition of the human DNA deaminase APOBEC3BSemantic proximity Read ↗

Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment.Semantic proximity Read ↗

Substrate sequence selectivity of APOBEC3A implicates intra-DNA interactions.Semantic proximity Read ↗

Antiviral Mechanism and Biochemical Basis of the Human APOBEC3 FamilySemantic proximity Read ↗

Creating RNA Specific C-to-U Editase from APOBEC3A by Separation of Its Activities on DNA and RNA Substrates.Semantic proximity Read ↗

Structure-Based Design of First-Generation Small Molecule Inhibitors Targeting the Catalytic Pockets of AID, APOBEC3A, and APOBEC3BSemantic proximity Read ↗

Insights into DNA substrate selection by APOBEC3G from structural, biochemical, and functional studies.Semantic proximity Read ↗

Guardian ubiquitin E3 ligases target cancer-associated APOBEC3 deaminases for degradation to promote human genome integrity.Semantic proximity Read ↗

Structure-guided inhibition of the cancer DNA-mutating enzyme APOBEC3ASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.